Researchers Receive $3.2 Million to Study Efficacy of Mind-body Practices in Improving Pain, Surgical Outcomes

Can mind-body practices such as gentle yoga or self-reflection benefit patients undergoing surgery? It’s a question that researchers at Wake Forest University School of Medicine are examining with the support of a five-year, $3.2 million grant from the National Cancer Institute (NCI).

New Study in JNCCN Presents Evidence for ‘Tough Conversations’ Around Racism in Access to Cancer Care

A study in JNCCN, led by researchers at Duke University School of Medicine, found that Non-Hispanic Black patients were less likely to receive guideline-appropriate treatment for ovarian cancer compared to Non-Hispanic White patients, even after adjusting for healthcare access issues.

MD Anderson Research Highlights for October 19, 2022

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a combination approach to overcome PARP inhibitor resistance in breast and ovarian cancers, a deeper understanding of STAT3 mutations as drivers of disease progression, insights into the “obesity paradox” in men with advanced melanoma, a prognostic model for rapidly progressing vestibular schwannoma, and a role for cellular trafficking proteins in creating a metastasis-promoting lung cancer microenvironment.

Machine learning creates opportunity for new personalized therapies

Researchers at the University of Michigan Rogel Cancer Center have developed a computational platform that can predict new and specific metabolic targets in ovarian cancer, suggesting opportunities to develop personalized therapies for patients that are informed by the genetic makeup of their tumors. The study appeared in Nature Metabolism.

JMIR Cancer | The Information Needs of Patients With Ovarian Cancer

JMIR Publications recently published “Understanding the Information Needs of Patients With Ovarian Cancer Regarding Genetic Testing to Inform Intervention Design: Interview Study” in JMIR Cancer, which reported that experts in gynecological cancer care recommend that all patients with invasive or high-grade ovarian cancer (OC) undergo genetic testing. However, even patients who intend to take or have taken genetic tests have many unaddressed information needs regarding genetic testing. Existing genetic counseling falls short of adequately addressing this challenge.

Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers

Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or in combination with another anticancer drug (pembrolizumab) may be effective in treating several types of late-stage cancers in some patients.

MD Anderson Research Highlights for May 4, 2022

Featured studies include clinical advances with a new combination therapy targeting angiogenesis in platinum-resistant ovarian cancer and a promising immunotherapy combination for kidney cancer, plus laboratory studies that focus on targeting ferroptosis in specific lung cancers, developing chimeric antigen receptor (CAR) T cell therapies for blastic plasmacytoid dendritic cell neoplasms, and characterizing racial and ethnic disparities in breast cancer early detection.

Roswell Park and University of Chicago Medicine Comprehensive Cancer Centers Awarded Nearly $9M for Ovarian Cancer Research

Researchers from Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center are combining efforts after together securing a nearly $9 million grant from the National Cancer Institute (NCI) to develop new and better treatments for ovarian cancer.

Women’s Wellness: Types of Gynecologic Cancers and their Warning Signs

September is Gynecologic Cancer Awareness Month. Rutgers Cancer institute of New Jersey Gynecologic Oncology Chief Dr. James Aikins reminds women about the types of gynecologic cancers and their warning signs

Experimental Model of Ovarian Cancer Shows Effect of Healthy Cell Arrangement in Metastasis

A key element to slowing metastasis in ovarian cancer is understanding the mechanisms of how tumor cells invade tissues. In APL Bioengineering, biophysics researchers explain how microscopic defects in how healthy cells line up can alter how easily ovarian cancer cells invade tissue. Using an experimental model, the group found that disruptions in the normal cellular layout, called topological defects, affect the rate of tumor cell invasion.

Dr. Beth Karlan receives lifetime achievement award for contributions to gynecologic oncology

Internationally renowned physician-scientist Dr. Beth Karlan, director of cancer population genetics at the UCLA Jonsson Comprehensive Cancer Center, is being honored with the Lifetime Achievement Award from the International Gynecologic Cancer Society (IGCS) for her contributions to gynecologic cancer research and clinical practice.

Mayo Clinic scientists advance breast, ovarian cancer research with cryo-electron microscopy

Using advanced imaging technology, Mayo Clinic scientists have provided an unprecedented understanding of the BRCA1-BARD1 protein complex, which is often mutated in patients with breast or ovarian cancer. Their paper, published in Nature, identifies aspects of how BRCA1-BARD1 functions, supporting future translational research, cancer prevention efforts and drug development.

Mayo Clinic researchers develop test to measure effect of breast cancer gene variants

Researchers at Mayo Clinic have combined results from a functional test measuring the effect of inherited variants in the BRCA2 breast and ovarian cancer gene with clinical information from women who received genetic testing to determine the clinical importance of many BRCA2 variants of uncertain significance (VUS). The findings were published today in a study in the American Journal of Human Genetics.

Study Identifies Never-Before-Seen Dual Function in Enzyme Critical for Cancer Growth

In developing therapies for hard-to-treat breast and ovarian cancers in patients with BRCA gene mutations, scientists aim to identify ways to keep cancer cells from using DNA break repair pathways. New findings demonstrate a previously-unknown capability for polymerase theta (pol theta) – a key enzyme in this repair function – that shows promise as a new avenue for treatment development.

Wistar Scientists Discover Link Between a Genetic Driver of Ovarian Cancer and Metabolism, Opening the Way for New Therapeutic Strategies

Wistar scientists found mutations that inactivate the ARID1A gene in ovarian cancer increase utilization of the glutamine amino acid making cancer cells dependent on glutamine metabolism. Researchers also showed that pharmacologic inhibition of glutamine metabolism may represent an effective therapeutic strategy for ARID1A-mutant ovarian cancer.

Ovarian Cancer Screening Study Focuses on Early Detection in Women at Low Risk

Atlantic Health System is enrolling women in a landmark study that uses a simple blood test for the CA-125 protein to screen women who are at low risk for ovarian cancer. The purpose of the clinical trial is to help determine whether this test can catch ovarian cancer early in women who would not normally be screened for it. Atlantic Health System hospitals are the only centers in the New York metro region to participate in the study, and have the third highest enrollment numbers in the nation.

Cancer Research Institute Goes Virtual for Its Immunotherapy Patient Summit Series, Connecting Patients and Caregivers with Leading Experts in Cancer Immunotherapy

Free virtual event October 2-3 connecting cancer patients and caregivers with leading immunotherapy experts and patient advocates treated with immunotherapy

What Every Woman Should Know About Preventing Gynecologic Cancers

The best defense against gynecologic cancer starts with preventative measures. When cancer is detected early, there is a better chance of having more effective treatment and better outcomes. While there is not a single screening test for all gynecologic cancers, learn about the ones that do exist.

Cancer, COVID and the Kentucky Economy: How ‘Sweet Annie’ Could Make an Impact

Used as a medicinal herb for centuries, Artemisia annua contains powerful compounds that make it a popular treatment for malaria. But with lab research showing these compounds may help treat a variety of cancers and even COVID-19, this plant is more relevant than ever — and UK is showing how we can take it from Kentucky fields to the research lab to our patients.

Latest developments on Cytoreductive Surgery & Hyperthermic Intraperitoneal Chemotherapy (CRT/HIPEC)

Mercy Medical Center is the first institution in the United States to study the role of CRS/HIPEC for newly diagnosed with ovarian, fallopian tube, or primary peritoneal cancers. Literature exists involving CRS/HIPEC in the role of recurrent disease and in the neoadjuvant setting; however, there is no published data on the role as a primary treatment option in the United States.